Glaxosmithkline Share News (GSK)

Dividends Calendar - Week Ahead

Dividends Calendar - Week Ahead

Dividends Calendar - Week Ahead

Dividends Calendar - Week Ahead

Dividends Calendar - Week Ahead

TOP NEWS: Greek Supreme Court To Rule On Legality Of Referendum

LONDON BRIEFING: BP Shares Upgraded Amid Relief Over US Settlement

Glaxo's ViiV Healthcare Signs China Manufacturing Deal With Desano

Dividends Calendar - Week Ahead

Dividends Calendar - Week Ahead

Manufacturing deal wins China cheap supply of GSK's new HIV drug

LONDON, July 2 (Reuters) - China will receive cut-price supplies of GlaxoSmithKline's new HIV drug Tivicay, following a deal for Shanghai-based Desano Pharmaceuticals to become an additional manufacturer of the medicine's active ingredient. The collaboration between GSK's HIV unit ViiV Heal

Scientists find new evidence on GSK vaccine link to narcolepsy

* GSK's Pandemrix shot linked to spike in narcolepsy cases * Incurable disorder causes sleep attacks and nightmares * Study finds link in flu protein found in H1N1 flu strain By Kate Kelland, Health and Science Correspondent LONDON, July 1 (Reuters) - Scientists investigating w

Tuesday share tips: Sky, BG Group, Vodafone

Sky´s decision to dedicate one of its channels solely to Formula 1 fits in well with its strategy as a content distributor, but a theoretical purchase of the franchise whole does not. Speculation has surfaced it might do just that, with Liberty Global and a group backed by the Qatari government also

Broker tips: GlaxoSmithKline, Astrazeneca, Hikma, Shire, Petrofac, ARM Holdings

HSBC initiated coverage of the European pharmaceuticals, saying the re-rating over the last few years looks set to continue. In terms of UK stocks, it initiated GlaxoSmithKline at 'buy' with a 1,700p price target, and AstraZeneca and Hikma Pharmaceuticals at 'hold' with 4,640p and 1,936p price targe

Liberum upgrades GlaxoSmithKline to 'hold'

Liberum upgraded GlaxoSmithKline to 'hold' from 'sell', but cut the price target to 1,350p from 1,400p. "Somewhat counter-intuitively, we believe a dividend cut is increasingly likely and necessary and therefore we upgrade," said Liberum. "With the recent fall in the share and the increasing likeli